We have located links that may give you full text access.
Predictive value of preoperative MRI features for the Ki-67 index in well-differentiated G1/G2 pancreatic neuroendocrine tumors.
Acta Radiologica 2019 March 27
BACKGROUND: The accurate estimation of the Ki-67 index of well-differentiated pancreatic neuroendocrine tumors (PanNET) not only guides curative management but also avoids unnecessary treatment.
PURPOSE: To investigate whether magnetic resonance imaging (MRI) features could preoperatively discriminate the Ki-67 index of well-differentiated G1/G2 PanNETs and to construct an individualized predictive model through developing a MRI-based nomogram.
MATERIAL AND METHODS: Ninety-nine patients with G1/G2 PanNETs were divided into Ki-67 index <5% (n = 58) and Ki-67 index ≥5% groups (n = 41). Multiparametric MRI features of two groups were assessed via uni- and multivariate logistic regression models. The MRI-based nomogram was then developed based on multivariable logistic analysis; the effectivity of the nomogram was validated according to the C-index, calibrations, and a decision curve analysis.
RESULTS: MRI features, including tumor size (odds risk [OR] = 7.791; P = 0.003) and the ADC values (OR = 0.245, P = 0.018) were significant independent risk factors for the high Ki-67 index (≥5%) of G1/2 PanNETs at multivariable analysis. The performance of the MRI-based nomogram (with a C-index of 0.825) was improved compared with that based on tumor size and ADC alone (with C-index values of 0.709 and 0.716, respectively). The calibration curve of the nomogram exhibited good consistency between evaluated and observed outcomes. The decision curve showed that the nomogram incorporating two MRI features had better clinical utilization than single features.
CONCLUSION: The preliminary MRI-based nomogram could be used to discriminate the Ki-67 index in well-differentiated G1/2 PanNETs.
PURPOSE: To investigate whether magnetic resonance imaging (MRI) features could preoperatively discriminate the Ki-67 index of well-differentiated G1/G2 PanNETs and to construct an individualized predictive model through developing a MRI-based nomogram.
MATERIAL AND METHODS: Ninety-nine patients with G1/G2 PanNETs were divided into Ki-67 index <5% (n = 58) and Ki-67 index ≥5% groups (n = 41). Multiparametric MRI features of two groups were assessed via uni- and multivariate logistic regression models. The MRI-based nomogram was then developed based on multivariable logistic analysis; the effectivity of the nomogram was validated according to the C-index, calibrations, and a decision curve analysis.
RESULTS: MRI features, including tumor size (odds risk [OR] = 7.791; P = 0.003) and the ADC values (OR = 0.245, P = 0.018) were significant independent risk factors for the high Ki-67 index (≥5%) of G1/2 PanNETs at multivariable analysis. The performance of the MRI-based nomogram (with a C-index of 0.825) was improved compared with that based on tumor size and ADC alone (with C-index values of 0.709 and 0.716, respectively). The calibration curve of the nomogram exhibited good consistency between evaluated and observed outcomes. The decision curve showed that the nomogram incorporating two MRI features had better clinical utilization than single features.
CONCLUSION: The preliminary MRI-based nomogram could be used to discriminate the Ki-67 index in well-differentiated G1/2 PanNETs.
Full text links
Related Resources
Trending Papers
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Anti-Arrhythmic Effects of Heart Failure Guideline-Directed Medical Therapy and Their Role in the Prevention of Sudden Cardiac Death: From Beta-Blockers to Sodium-Glucose Cotransporter 2 Inhibitors and Beyond.Journal of Clinical Medicine 2024 Februrary 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app